Mining drug–disease relationships as a complement to medical genetics‐based drug repositioning: Where a recommendation system meets genome‐wide association studies
Authors:
- 23 January 2015
- journal article
- development
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 97 (5) , 451-454
Abstract
A novel recommendation‐based drug repositioning strategy is presented to simultaneously determine novel drug indications and side effects in one integrated framework. This strategy provides a complementary method to medical genetics‐based drug repositioning, which reduces the occurrence of false positives in medical genetics‐based drug repositioning, resulting in a ranked list of new candidate indications and/or side effects with different confidence levels. Several new drug indications and side effects are reported with high prediction confidences.Keywords
This publication has 5 references indexed in Scilit:
- Rational drug repositioning by medical geneticsNature Biotechnology, 2013
- Computational Drug Repositioning: From Data to TherapeuticsClinical Pharmacology & Therapeutics, 2013
- Use of genome-wide association studies for drug repositioningNature Biotechnology, 2012
- PREDICT: a method for inferring novel drug indications with application to personalized medicineMolecular Systems Biology, 2011
- Drug Target Identification Using Side-Effect SimilarityScience, 2008